HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer...(to our current or planned products;wheth...),Health

Date:12/14/2007

to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

VeraTag and HERmark are trademarks of Monogram Biosciences, Inc. Herceptin is a registered trademark of Genentech, Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@ jeremiah.hall@

monogrambio.com fkhealth.com

'/>"/>

SOURCE Monogram Biosciences, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Tapestry Reports Second Quarter 2007 Results
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results